Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ICUI vs LIVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LIVN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

LIVN Overall Winner 6-Pillar Tally: ICUI 2 – 4 LIVN Matrix Metrics: ICUI 3 – 7 LIVN

As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over ICU Medical Inc (ICUI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ICUI carries a Unified Composite Score of 41.4/100 (SELL) at $175.76 (18.2x Forward P/E, 6.7% operating margin), whereas LIVN carries 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin).

  • Composite vs. Pillar Nuance: While ICUI currently prints a higher short-term Unified Composite Score (41.4/100 SELL vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 6.7% operating margin) and revenue trajectory (+9.9% vs. +4.4% YoY).
  • Defensive Composite Rating Caution: Although LIVN compares more favorably head-to-head, both ICUI (41.4/100 SELL) and LIVN (38.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ICUI vs LIVN
ICUI NASDAQ
ICU Medical Inc
Surgical & Medical Instruments & Apparatus
$175.76
-1.52% 1D
Market Cap $4.5B
TTM Revenue $2.18B
Forward P/E 18.2x
Beta / 30D Vol 0.89β · 40% Vol
Unified Composite Score
41.4 / 100 SELL
Tech 23.0 Fund 35.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.1 · SMA20: $172.00 · SMA50: $165.05
LIVN NASDAQ Head-to-Head Winner
LivaNova PLC Ordinary Shares
Electromedical & Electrotherapeutic Apparatus
$92.07
-2.61% 1D
Market Cap $5.1B
TTM Revenue $1.51B
Forward P/E 19.5x
Beta / 30D Vol 0.98β · 67% Vol
Unified Composite Score
38.5 / 100 SELL
Tech 23.0 Fund 40.0 Flow 70.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $87.27 · SMA50: $81.35

6-Pillar Scorecard Institutional Category Breakdown (ICUI 2 – 4 LIVN)

Columns: Metric · ICUI · LIVN
1. Valuation Multiples ICUI
Forward P/E 18.2x 19.5x
Trailing P/E 74.7x 26.5x
PEG Ratio 0.09x 0.93x
EV / Revenue 2.0x 3.2x
2. Growth & Scale LIVN
Revenue Growth (YoY) +4.4% +9.9%
Earnings Growth (YoY) -46.9% -78.2%
TTM Revenue (USD) $2.18B $1.51B
Market Cap $4.5B $5.1B
3. Profitability & Quality LIVN
Gross Margin 38.9% 67.6%
Operating Margin 6.7% 14.3%
Net Profit Margin 2.8% 13.0%
Return on Equity (ROE) 2.8% 15.5%
4. Balance Sheet & Cash Flow ICUI
Cash Generation (TTM) $346M EBITDA $129M
Cash Flow Margin 15.9% EBITDA Mgn 8.6%
Net Cash / Leverage $87.62 Book/Sh · 2.8% ROE $206M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LIVN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 39.9% (2nd %ile) 36.9% (11th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat LIVN
OpEx & R&D Intensity 32.2% of Rev ($703M) 53.3% of Rev ($803M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ICUI (3) vs LIVN (7)
Institutional Metric ICUI LIVN Criterion Row Edge
Market Capitalization
Scale
$4.5B $5.1B Larger Scale LIVN
Trailing P/E Ratio
Valuation
74.7x 26.5x Lower Multiple LIVN
Forward P/E Ratio
Valuation
18.2x 19.5x Lower Multiple ICUI
Revenue Growth (YoY)
Growth
+4.4% +9.9% Higher Growth LIVN
Operating Margin (TTM)
Profitability
6.7% 14.3% Higher Margin LIVN
Net Profit Margin
Profitability
2.8% 13.0% Higher Margin LIVN
Return on Equity (ROE)
Capital Efficiency
2.8% 15.5% Higher ROE LIVN
52-Week Range Position
Momentum
78% ($113–$193) 84% ($52–$99) Stronger Trend LIVN
Beta / 30D Volatility
Risk Regime
0.89β · 40% Vol 0.98β · 67% Vol Lower Realized Risk ICUI
Unified Institutional Score
Composite Signal
41.4 / 100 (SELL) 38.5 / 100 (SELL) Higher Composite ICUI
Trailing 12M Revenue (USD)
Operating Scale
$2.18B $1.51B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
38.9% 67.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.09x PEG · 2.0x EV/Rev 0.93x PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$346M EBITDA ($87.62 Book/Sh · 2.8% ROE) $129M ($206M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LIVN +8.1 pp
ICUI: +9.28% · LIVN: +17.38%
3M Horizon LIVN +20.8 pp
ICUI: -3.87% · LIVN: +16.93%
6M Horizon ICUI +8.82 pp
ICUI: +33.85% · LIVN: +25.03%
1Y Horizon LIVN +39.72 pp
ICUI: +31.13% · LIVN: +70.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICUI vs LIVN. Trailing 12-month operating profitability (ICUI 6.7% vs LIVN 14.3%) and valuation multiples (ICUI 18.2x vs LIVN 19.5x Forward P/E) are benchmarked directly in Pillar 4 below.

ICUI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.18B
Gross Margin38.9%
Op. Margin6.7%
ROE / Fwd P/E2.8% · 18.2x
LIVN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.51B
Gross Margin67.6%
Op. Margin14.3%
ROE / Fwd P/E15.5% · 19.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ICUI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 39.9%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICUI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVN CONSOLIDATION
97d in phase · OBV NEUTRAL
Current IV 36.9%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LIVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ICUI Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $4.5B market capitalization and 6.7% operating margin.
OpEx & R&D Reinvestment 32.2% of Rev ($703M)
90D Engineering Disclosures 0 Published
LIVN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.1B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 53.3% of Rev ($803M)
90D Engineering Disclosures 0 Published

Investor FAQ ICUI vs LIVN Key Questions & Quantitative Answers

As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over ICU Medical Inc (ICUI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ICUI carries a Unified Composite Score of 41.4/100 (SELL) at $175.76 (18.2x Forward P/E, 6.7% operating margin), whereas LIVN carries 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin). Composite vs. Pillar Nuance: While ICUI currently prints a higher short-term Unified Composite Score (41.4/100 SELL vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 6.7% operating margin) and revenue trajectory (+9.9% vs. +4.4% YoY). Defensive Composite Rating Caution: Although LIVN compares more favorably head-to-head, both ICUI (41.4/100 SELL) and LIVN (38.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

LIVN leads the Growth & Scale pillar: ICUI posts +4.4% YoY revenue growth and -46.9% YoY earnings growth on $2.18B TTM revenue (38.9% gross margin, 6.7% operating margin), compared with LIVN at +9.9% YoY revenue growth and -78.2% YoY earnings growth on $1.51B TTM revenue (67.6% gross margin, 14.3% operating margin). On trailing 12-month operating scale, ICUI generates $2.18B in USD-normalized revenue versus $1.51B for LIVN. In operating R&D and SG&A reinvestment, ICUI deploys 32.2% of Rev ($703M) (0 90-day corporate R&D disclosures) versus 53.3% of Rev ($803M) (0 disclosures) for LIVN.

ICUI screens cheaper on headline valuation multiples. ICUI trades at 18.2x Forward P/E, 74.7x Trailing P/E, 0.09x PEG, and 2.0x EV/Revenue (15.9% EBITDA margin), whereas LIVN trades at 19.5x Forward P/E, 26.5x Trailing P/E, 0.93x PEG, and 3.2x EV/Revenue (8.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICUI (2.8% ROE) versus LIVN (15.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ICUI carries 39.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.89β · 40% Vol realized risk). By comparison, LIVN carries 36.9% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.98β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.